{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:58:09Z","timestamp":1790816289712,"version":"4.1.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PN) are peripheral nerve sheath tumors that can significantly affect the quality of life. Until recently, surgery was the only treatment for these tumors. However, in most cases, surgery cannot achieve complete tumor removal and carries a high risk of postoperative deficits. Therefore, the recent approval of the MEK inhibitor selumetinib for the treatment of NF1-associated PN provides a long-awaited novel therapeutic option. Here, we report our experience with MEK inhibitor treatment in 12 pediatric NF1 patients with inoperable symptomatic PN. Eight patients received trametinib (median therapy duration 12.13 months and range 4\u201329 months), and four patients received selumetinib (median therapy duration 6.25 months and range 4\u201311 months). Volumetric magnetic resonance imaging (MRI) after 6 months of treatment was available for seven trametinib patients (median tumor volume reduction of 26.5% and range 11.3\u201355.7%) and two selumetinib patients (21.3% tumor volume reduction in one patient and +3% tumor volume change in the other one). All patients reported clinical benefits such as improved range of motion or reduced disfigurement. Therapy-related adverse events occurred in 58.3% of patients and mainly consisted of skin toxicity, paronychia, and gastrointestinal symptoms. Two patients discontinued trametinib treatment after 14 and 29 months when severe skin toxicity occurred and no further reduction of tumor size was observed. In one patient, discontinuation of therapy resulted in a 27.2% tumor volume increase as demonstrated on volumetric MRI 6 months later. Our data show that MEK inhibition is a novel therapeutic approach for inoperable PN with promising results and a manageable safety profile.<\/jats:p>","DOI":"10.1055\/s-0041-1740549","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:20:36Z","timestamp":1639527636000},"page":"052-060","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option"],"prefix":"10.1055","volume":"53","author":[{"given":"Pia","family":"Vaassen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola Reinhard","family":"D\u00fcrr","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Sana Kliniken Duisburg, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jmg.26.11.704","article-title":"A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity","volume":"26","author":"S M Huson","year":"1989","journal-title":"J Med Genet"},{"issue":"08","key":"ref2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmg.37.8.632","article-title":"Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland","volume":"37","author":"M Poyhonen","year":"2000","journal-title":"J Med Genet"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"M Lammert","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref4","first-page":"5","volume-title":"Genetics and Pathway in Neurofibromatosis Type 1","author":"E Denayer","year":"2020"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"S Akshintala","year":"2020","journal-title":"Neuro-Oncol"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"A M Gross","year":"2018","journal-title":"Neuro-Oncol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits","volume":"159","author":"R Nguyen","year":"2011","journal-title":"J Pediatr"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994","volume":"131","author":"M N Needle","year":"1997","journal-title":"J Pediatr"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","article-title":"Resection of plexiform neurofibromas in children with neurofibromatosis type 1","volume":"31","author":"F Canavese","year":"2011","journal-title":"J Pediatr Orthop"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"W J Jessen","year":"2013","journal-title":"J Clin Invest"},{"issue":"26","key":"ref11","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type-1 related plexiform neurofibromas","volume":"375","author":"E Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"ref12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"A M Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0039-1691830","article-title":"Trametinib induces neurofibroma shrinkage and enables surgery","volume":"50","author":"P Vaassen","year":"2019","journal-title":"Neuropediatrics"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"R E Ferner","year":"2007","journal-title":"J Med Genet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I\/IIa study","volume":"36","author":"G B McCowage","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"E Dombi","year":"2013","journal-title":"Neurology"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00381-021-05127-6","article-title":"Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1","volume":"37","author":"H Toledano","year":"2021","journal-title":"Childs Nerv Syst"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"S Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","author":"A M Gross","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN)","volume":"36","author":"B Geoerger","year":"2018","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40272-020-00399-y","article-title":"Selumetinib in the treatment of symptomatic intractable plexiform neurofibromas in neurofibromatosis type 1: a prospective case series with emphasis on side effects","volume":"22","author":"F Baldo","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"01","key":"ref23","first-page":"a095","article-title":"The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas","volume":"2","author":"S Jackson","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-021-01032-y","article-title":"Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib","volume":"23","author":"R Galvin","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1200\/JCO.2020.38.15_suppl.3612","article-title":"Phase II trial of the MEK 1\/2 inhibitor selumetinib (AZD 6244, ARRY-142886 hydrogen sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"38","author":"G O'Sullivan Coyne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1753-2000-2-37","article-title":"Regulation (EC) no 1901\/2006 on medicinal products for paediatric use & clinical research in vulnerable populations","volume":"2","author":"B Lehmann","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"e0006578","DOI":"10.1371\/journal.pntd.0006578","article-title":"Risk of adverse swallowing events and choking during deworming for preschool-aged children","volume":"12","author":"J W Kernell","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/archdischild-2019-317512","article-title":"The KidzMed project: teaching children to swallow tablet medication","volume":"105","author":"Y Tse","year":"2020","journal-title":"Arch Dis Child"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1542\/peds.2006-1488","article-title":"Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV\/AIDS","volume":"119","author":"P A Garvie","year":"2007","journal-title":"Pediatrics"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1542\/peds.2014-2114","article-title":"Effectiveness of pediatric pill swallowing interventions: a systematic review","volume":"135","author":"A Patel","year":"2015","journal-title":"Pediatrics"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/cancers13081905","article-title":"Contemporary neoadjuvant therapies for high-risk melanoma: a systematic review","volume":"13","author":"K Boulva","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"S J Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1097\/MPH.0000000000000364","article-title":"Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma","volume":"37","author":"S Modak","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"M Banks","year":"2017","journal-title":"Cardiovasc Toxicol"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pde.13038","article-title":"Cutaneous reactions in children treated with the mitogen-activated protein kinase extracellular signal-regulated kinase inhibitor trametinib for neural tumors","volume":"34","author":"C Boull","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in Neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"L J Klesse","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1002\/cam4.3910","article-title":"Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma","volume":"10","author":"R Ronsley","year":"2021","journal-title":"Cancer Med"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/pde.14276","article-title":"Treatment of MEK inhibitor-induced paronychia with doxycycline","volume":"37","author":"Q Sun","year":"2020","journal-title":"Pediatr Dermatol"}],"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1740549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:12:09Z","timestamp":1643069529000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1740549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":38,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,24]]},"published-print":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1740549","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]}}}